Rituximab (RTX), a chimeric monoclonal antibody targeted against CD20, has been used to treat refractory inflammatory myopathies (IIM). The primary objective of this study was to retrospectively assess the efficacy of RTX in reducing disease activity in patients with IIM refractory to conventional therapy. Secondary aim was the evaluation of adverse events (AE) during the treatment period. We examined 26 patients with a diagnosis of IIM, referred to our Rheumatology Unit and treated with RTX for active refractory disease. Patients were treated with RTX 1000 mg i.v., twice, with a 2-week interval. RTX treatment was associated with a significant reduction of creatine kinase (p=0.001) after six months compared to the baseline, an improved muscular strength measured with MMT8 (p<0.001) and a reduction of the extramuscular activity of the disease measured with MYOACT (p<0.001). In particular, RTX improved DM skin rash, arthritis and pulmonary manifestations. Autoantibody positivity (in particular antisynthetase, anti-SRP and antiRo/SSA), and a disease duration <36 months at the moment of the treatment are associated with a better response rate. Treatment with RTX was also associated with a reduction of the mean daily dose of steroids needed to control disease activity (p=0.002). Our results have confirmed that RTX is efficacious in the treatment of refractory IIM. Ad hoc controlled trials are needed to better clarify the specific subset of patients who may better respond to the treatment and the optimal therapeutic schedule.
n INTRODUCTION I diopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases characterized by inflammation of the skeletal muscles and involvement of internal organs such as lungs, heart, esophagus and, rarely, kidneys. IIMs are classifiable in different subtypes, the most common are polymyositis (PM), inclusion body myositis (IBM), necrotizing autoimmune myopathy (NAM) and dermatomyositis (DM) (1) . Some patients may have a peculiar clinical pattern characterized by arthritis, myositis, and interstitial lung disease (ILD) with positivity for antisynthetase autoantibodies (ASA) and are further classifiable as antisynthetase syndrome (ASS) (2) . Although corticosteroids are usually used as a first line therapy in the treatment of IIM (3), there are no standard therapeutic guidelines for its treatment, particularly due to the rarity of the disease and the presence of different subtypes, making it difficult to design randomized controlled clinical trials (4) . A large number of patients are therefore treated with high cumulative doses of steroids and/or different immunosuppressive drugs to control the disease (3) . In the first RCT, the Rituximab in Myositis (RIM) trial, while the trial failed to achieve the primary efficacy endpoint (12, 14, 15) , RTX was able to reduce the clinical activity and the daily prednisone dose taken by refractory patients. In the second trial, conducted in 12 patients with ASA positivity, RTX was reported to be efficacious on lung and muscular involvement (13) . The primary aim of our study was to evaluate the efficacy of RTX in a monocentric cohort of patients with refractory IIM. The secondary aim was to evaluate the adverse events (AE) occurring during the treatment.
n MATERIALS AND METHODS
We retrospectively evaluated consecutive in-and out-patients with a definite diagnosis of PM or DM according to the Bohan and Peter criteria (16, 17) or a diagnosis of IBM according to the Griggs criteria (18 3) physicians' global activity assessment by a 10 cm VAS (pVAS) (18); 4) creatine kinase (CK) levels. Patients' sera were tested for antinuclear autoantibody (ANA) and for extractable nuclear antigens (ENA) by counter immunoelectrophoresis for sera collected between 2005 and 2014; the only myositis specific antibodies (MSA) available were anti-Jo1, while myositis associated antibodies (MAA) available were anti-Ku and anti-SSA. Starting from 2015, sera were also tested for MSA and MAA by line blot (Myositis profile 3, Euroimmun, Lubeck) and the following specificity were available: Mi-2, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52. The efficacy of the treatment was assessed after 6 months, and was evaluated according to a simplified version of IM-ACS definition of improvement (19) . The improvement was defined as major if the patient showed an increase of at least 15% in muscle strength by MMT8 and 30% reduction in CPK after 6 months (20) . The improvement was defined as minor if the patient obtained improvement in at least 2 of the four IMACS core set measures: 15% improvement in total MMT8, 20% improvement in pVAS, 20% improvement in the MYOACT score, 30% reduction of CK (20) . No more than 1 measure should worsen by ≥25% and the MMT could not be one of the worsening measures. To evaluate the toxicity, the appearance of AE was scored according to common terminology criteria for adverse events (CTCAE) v4.0 according to the following scale: grade 1: mild, grade 2: moderate; grade 3: severe, grade 4: very severe. All the adverse events not attributable to any other disease or concomitant medication were taken into account. AE were classified as directly related to treatment if the EA was associated with the mechanism of action of the drug (e.g. infections), or not directly related to the treatment if the EA was not expected and/or related to allergic sensitization (e.g. sneezing, difficulty in breathing, cramps, and vomiting). The following data were also collected: indications to start treatment, previous and 
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concomitant therapies, disease-free interval, number and timing of retreatment.
Statistical analysis
The variables were expressed as mean +/-standard deviation (SD). The difference between baseline and after six months from the therapy was calculated using the parametric test (ANOVA) when the variables were normally distributed or using nonparametric test Mann-Whitney and KruskalWallis when not normally distributed (SPSS statistics 19, IBM). A multivariate analysis was performed to identify predictive factors of the response to the treatment.
n RESULTS (Table I) . Seventeen patients were receiving Iv-Ig. ANA were positive in 13 (50%) patients; anti-ENA antibodies were observed in 13 patients (50%). Autoantibodies specificities observed are reported in Table I .
Baseline characteristics

Evaluation after six months
The clinimetric parameters included in the study at baseline and after 6 months from treatment are reported in Table II Table III .
Last follow up
In December 2016, twenty-one patients were still in follow-up. The mean followup duration was 48.6±38.8 months.
During the follow-up, 8 responder patients relapsed on average after 17±18 months from the treatment. All the relapsed patients were successfully retreated with RTX. Among the 5 patients who did not continue the follow up: 1 patient was lost to follow-up and four patients died for diseaserelated causes with a mean disease duration of 80.7 months (min 23, max 144). The disease-related causes were: respiratory failure due to muscle weakness in a patient with IBM, heart involvement in two DM patients (one for cardiac sudden death and one for heart insufficiency), severe pneumonia in one patient with PM. The average time between the last infusion of RTX and the death was 45 months (min 14 -max 94). 
ORIGINAL PAPER n DISCUSSION AND CONCLUSIONS
Literature data show a strong evidence for a critical role of B cells in IIM, in particular for DM (21, 22) as well as, more recently, in the pathogenesis of PM and IBM (23) . The results of our study confirm the efficacy of RTX in the treatment of refractory IIM. The treatment was effective both in muscular and in some extramuscular manifestations of the disease. Prognostic factors for a higher response rate were the autoantibody positivity (antisynthetase autoantibody, anti-SRP and anti-Ro/SSA). The extramuscular manifestations that showed an improvement after the treatment were articular, skin and respiratory involvement, while dysphagia improved only in a small group of patients. Patients with IBM did not improve with the treatment. The treatment of patients with shorter disease duration seems to be associated with a better outcome, in particular when treatment was started in patients with a disease duration shorter than 36 months. Literature data confirm our observations about the good efficacy in DM patients (24) (25) (26) (27) , in particular in patients with the juvenile form (28) . Several studies also reported a good outcome in patients with lung disease, in particular when associated with antisynthetase autoantibodies positivity (13, (29) (30) (31) (32) (33) (34) . No clear data are available in medical literature about the efficacy of RTX in articular and esophageal manifestations on IIM and in the treatment of IBM. Our observations about a better prognosis in patients with autoantibodies positivity are consistent with the literature, in particular when associated with antisynthetase autoantibodies positivity (5, 7, 28, 31, 33, 35) . Also anti-SRP positivity was reported to be associated to a better response to RTX treatment (36, 37) . In a recent publication on 17 patients with anti-SRP associated myositis, 13/17 patients improved after the treatment (38) . We observed, in our population, that a good outcome may be reached in patients with a disease duration lower than three years. This aspect is partially in contrast with other reports in medical literature, where some authors described a better response in patients with a disease duration of less than 1 year (30) . In addition, in our study, multivariate analysis identified disease duration as the only independent factor to predict the response to RTX. In our cohort of patients RTX was also effective in reducing the corticosteroid daily dose, and these data are consistent with other studies (13, 39) . Patients with IIM are often treated with high cumulative corticosteroids doses and a reduction of the daily dose may lower the incidence of side effects, such as the steroid myopathy (40) . We also observed one moderate and four severe AEs: we have reported two infections, two immune-mediated reactions and one skin rash. A higher prevalence of these AEs in IIM patients was also reported by other authors; in particular, infusion reactions (35, 39, 41) and infections have been correlated to treatment with RTX. Although infections during treatment with RTX in IIM patients were usually mild (39) , rare cases of severe AEs have been reported including viral and bacterial infections (41, 42) and few cases of multifocal leukoencephalopathy (43, 44). 
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The main point of strength of our work is the large monocentric group of patients with IIM treated with RTX and the long duration of the follow-up, although the main limitation is the retrospective data collection.
Although the safety profile does not seem free from adverse events, RTX certainly represents a new perspective for the therapeutic approach of IIM. Further ad hoc controlled trials are needed to better clarify the specific subset of patients associated with a higher response rate to the treatment and the specific schedule of management. 
